Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to -$1.2 million.

  • Standard Biotools' Tax Provisions fell 113050.85% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year decrease of 82697.1%. This contributed to the annual value of $573000.0 for FY2024, which is 52.63% up from last year.
  • Standard Biotools' Tax Provisions amounted to -$1.2 million in Q3 2025, which was down 113050.85% from -$609000.0 recorded in Q2 2025.
  • Standard Biotools' Tax Provisions' 5-year high stood at $301000.0 during Q2 2023, with a 5-year trough of -$1.7 million in Q1 2021.
  • Over the past 5 years, Standard Biotools' median Tax Provisions value was -$200000.0 (recorded in 2025), while the average stood at -$427315.8.
  • As far as peak fluctuations go, Standard Biotools' Tax Provisions soared by 72045.45% in 2024, and later plummeted by 166153.85% in 2025.
  • Over the past 5 years, Standard Biotools' Tax Provisions (Quarter) stood at -$814000.0 in 2021, then surged by 108.6% to $70000.0 in 2022, then tumbled by 162.86% to -$44000.0 in 2023, then soared by 720.45% to $273000.0 in 2024, then plummeted by 545.42% to -$1.2 million in 2025.
  • Its Tax Provisions stands at -$1.2 million for Q3 2025, versus -$609000.0 for Q2 2025 and -$200000.0 for Q1 2025.